ALX Oncology (ALXO) SVP Shelly Pinto sells shares to pay taxes

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. reported an insider stock sale by Shelly Pinto, the company’s SVP, Finance and CAO. On 01/06/2026, Pinto sold 3,925 shares of common stock at a weighted average price of $1.11 per share, in multiple trades between $1.11 and $1.12.

According to the filing, the sale was made to cover the reporting person’s tax obligations related to the vesting of restricted stock units. After this transaction, Pinto beneficially owned 88,273 shares of ALX Oncology common stock, which includes 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.

Insider Trade Summary

Net Seller: 3,925 shares ($4,357)

Net Sell 1 txn

Insider Pinto Shelly

Role SVP, FINANCE AND CAO

Sold 3,925 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,925	$1.11	$4K

Holdings After Transaction: Common Stock — 88,273 shares (Direct)

Footnotes (1)

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinto Shelly

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE AND CAO

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		3,925	D	$1.11(2)	88,273(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025.

	/s/ Shelly Pinto	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ALX Oncology (ALXO) disclose in this Form 4?

The filing reports that SVP, Finance and CAO Shelly Pinto sold 3,925 shares of ALX Oncology common stock on 01/06/2026.

What was the sale price for the ALXO shares in Shelly Pinto’s transaction?

The shares were sold at a weighted average price of $1.11 per share, in multiple trades at prices ranging from $1.11 to $1.12, inclusive.

Why did Shelly Pinto sell ALX Oncology (ALXO) shares?

The filing states the shares were sold to satisfy the reporting person’s tax obligations in connection with the vesting of restricted stock units.

How many ALX Oncology shares does Shelly Pinto own after the reported sale?

After the transaction, Shelly Pinto beneficially owned 88,273 shares of ALX Oncology common stock.

Does Shelly Pinto’s reported ALXO ownership include shares from an employee stock purchase plan?

Yes. The reported 88,273 shares include 3,000 shares acquired under ALX Oncology’s employee stock purchase plan on December 31, 2025.

What is Shelly Pinto’s role at ALX Oncology (ALXO)?

Shelly Pinto is an officer of ALX Oncology, serving as SVP, Finance and Chief Accounting Officer (CAO).